Antibe Therapeutics Inc(Pre-Merger) ATBPF

Upcoming Discussion ...

[MrMugsy]

January 18th ...

Learn about the benefits of otenaproxesul’s new formulation, dive into Antibe’s recently released data and Phase II planning, and explore the future of pain management.

--------------

The future of pain management ... that's likely going to require some reading-between-the-lines.

[Benedictus]

I recall Dan saying a long while back that partnering opportunities for acute would be easier than chronic. Do you agree with that or is that just Dan speak in the same vein as his AME debacle "just a bump in the road"?   It would be really helpful to gain better understanding around partnering potential in a post p2 success scenario as the p3 funding gap looms quite large in my

[MrMugsy]

Regardless of easier or harder - both acute and chronic are huge markets on their own.  Also, acute is a short window for painkiller usage which makes OTENA a perfect candidate.  Chronic is more complex in regimen design w.r.t. the liver (IMO) and success in chronic will come from success in acute ... first. Remember - as far as I'm concerned ... I'll take a chronic flare-up